Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. - Wikidata - awgldk - TriplyDB

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

http://www.wikidata.org/entity/Q33436217

about

Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents Two new cytotoxic ent-clerodane diterpenoids from Scutellaria barbata Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle Designing a broad-spectrum integrative approach for cancer prevention and treatment.Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263.Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor.Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.Control of AIF-mediated cell death by antagonistic functions of CHIP ubiquitin E3 ligase and USP2 deubiquitinating enzyme.The mitochondrial death pathway: a promising therapeutic target in diseases Wogonin induces reactive oxygen species production and cell apoptosis in human glioma cancer cells.Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine.Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity.A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut.Hedyotis diffusa Combined with Scutellaria barbata Are the Core Treatment of Chinese Herbal Medicine Used for Breast Cancer Patients: A Population-Based Study.Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study.Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines.New neo-clerodane diterpenoids from Scutellaria strigillosa with cytotoxic activities.Phytoagent deoxyelephantopin derivative inhibits triple negative breast cancer cell activity by inducing oxidative stress-mediated paraptosis-like cell death Delayed growth of glioma by Scutellaria flavonoids involve inhibition of Akt, GSK-3 and NF-κB signaling.Cytotoxic and antioxidant properties of selected Scutellaria species from the Western Ghats of Peninsular India.Cancer chemoprevention and therapy using chinese herbal medicine.Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: in vitro and in vivo studies.Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention

P2860

Q26800890-4EA58769-D2A4-4463-8382-E37701DCA280 Q28294942-C685E786-E928-4210-9699-6B9BF8B22F34 Q28480504-27A882BD-E1BA-4D1B-8F54-9375A76442D8 Q28732762-DE6E4683-5F7F-47A5-B144-DAA7F0F66AB3 Q30736359-00F5F854-8F71-4E75-ABE8-9CD3806370F8 Q33415723-B1B3557E-E2E0-4049-9877-E3AB0E881B21 Q33689527-8CF776C5-882C-4DBD-A8C5-3D4C97ADEE9B Q34264658-0736C38E-0331-448E-BD26-58D1C86BD6B0 Q34991655-586EEB4F-6C4C-4D9A-9D3B-A1C61B36A819 Q35210599-F0C2DD81-EAF7-4E81-955C-B0E4C3FC5C87 Q35831981-B16CC2A3-898F-4125-9BC8-59C59D71C3C3 Q36202313-499370A1-FB47-48D5-A0FC-D534DC2827F9 Q37368051-BCB502E0-083C-44F7-BE3C-4AD4C13A2730 Q37397870-67295737-88A2-4443-8E1C-89709D527428 Q37520219-B589F4A5-6B59-42A0-8281-735ABE59C01E Q37636074-E3646B9A-50DE-4547-A0B7-F141A0417836 Q37664685-089507B9-46CA-4A31-A029-42B193C7B2AC Q38798742-B71165B0-7305-4843-8996-17198984CEB4 Q39555290-E4350B52-9C7C-4B91-8959-F6340F81D038 Q39608832-A3D9C682-BE0B-4329-9953-0D460F232D4C Q40117223-28F5E833-96FD-4740-A66B-B7C41AA940A2 Q41343881-130D1FFA-1E10-4510-A37E-2BECCF4F18E1 Q41889454-B59DDC06-27C8-4194-90D2-A1C1C36C5B89 Q43830288-C1632D46-A46F-42F9-AD64-CC71828A1962 Q47327090-E4CADFF7-2B70-466C-B87A-A0C8BECD9FA9 Q55019482-786FC37A-B218-4BE2-A0FC-C7D077B4EB01 Q58793547-4C6BA3CC-AB84-4ECC-9DE3-A99D7A5C8E6C

P2860

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

http://www.wikidata.org/entity/Q33436217

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@ast

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@en

type

label

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@ast

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@en

prefLabel

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@ast

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@en

P1433

Q33436217-5D610DC0-1F0F-4FB9-BDBE-8B20BBDCAF9A

P1476

Q33436217-6E738390-EDB6-47CC-8553-EF7B74CD19D0

P2093

Q33436217-1B00C882-4413-4FA3-814D-F1B925969B10

Q33436217-5BCA2B60-D241-4A0B-8043-AD5AA32A1A9D

Q33436217-660DC3C3-2CE4-4106-AAA6-B1794A5FD27F

Q33436217-8CFAC0EB-7B6D-4548-9D61-B361CEA5183F

Q33436217-942C7913-A8D5-4E48-A561-C97E204C8697

Q33436217-A72809EC-87FC-496D-BB5B-861795931EA5

Q33436217-C3F82C23-D325-4160-8BDB-59CA91EA2124

Q33436217-C868A362-8ABC-4C88-9D5F-5C598CDE70B0

Q33436217-D0965229-923B-43C1-90A0-8C472B1C75B5

Q33436217-D199B5D6-6BDA-48FE-B197-1A1753E49B38

P2888

Q33436217-59A3D7AA-F756-49D3-BD33-3F7ED867A70D

P304

Q33436217-56A5BD22-D3CC-4EEE-AE0F-B1CB0EB15B1A

P31

Q33436217-34544E09-E37E-4154-935A-A5650F08918E

P356

Q33436217-285C4598-F21F-4D02-823A-C2BEC870E894

P407

Q33436217-0308D920-A434-47B5-90E0-0DC122BE952E

P433

Q33436217-0B15496B-C1F9-4C9C-84E7-A1441405889C

P478

Q33436217-2C399895-95B2-4889-8A42-2846A0BC22E7

P577

Q33436217-749F33DD-3818-440A-B33D-347743552EA0

P5875

Q33436217-2290E537-8BE3-4B30-8F76-6EDE596E5953

P6179

Q33436217-5039BBCB-8E0B-45ED-8CB8-52F64E97F3E7

P698

Q33436217-4DE1C15F-BFDF-4148-9AD4-73D072654B45

P921

Q33436217-3AD53BBE-5514-4BF6-8715-2F639E6B97BA

P356

S10549-006-9430-6

P1433

Breast Cancer Research and Treatment

P1476

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.

@en

P2093

Alejandra Perez

http://www.w3.org/2001/XMLSchema#string

Charles Vogel

http://www.w3.org/2001/XMLSchema#string

Debu Tripathy

http://www.w3.org/2001/XMLSchema#string

Elizabeth Tan Chiu

http://www.w3.org/2001/XMLSchema#string

Emma Shtivelman

http://www.w3.org/2001/XMLSchema#string

Hope Rugo

http://www.w3.org/2001/XMLSchema#string

Isaac Cohen

http://www.w3.org/2001/XMLSchema#string

Mark Shoemaker

http://www.w3.org/2001/XMLSchema#string

Mary Tagliaferri

http://www.w3.org/2001/XMLSchema#string

Michelle Melisko

http://www.w3.org/2001/XMLSchema#string

P2888

s10549-006-9430-6

P304

17-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-006-9430-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6687107

http://www.w3.org/2001/XMLSchema#string

P6179

1015743685

http://www.w3.org/2001/XMLSchema#string

P698

17111207

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial